IMS Health Australia-New Zealand - Pricing & Marketing Access

Publications 2003-2002

2003

Gordois AL, Scuffham PA, Gibbons D. 2002. The cost-effectiveness of outreach respiratory care for COPD patients. Professional Nurse 17: 504–507.

Gordois A, Scuffham P, Warren E, Ward S. 2003. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer 89: 634–640.

Shearer A, Scuffham P, Gordois A, Oglesby A. 2003. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care 26: 2305–2310.

Gordois A, Shearer A, Scuffham P, Oglesby A. 2003. The health care costs of diabetic peripheral neuropathy in the United Kingdom. The Diabetic Foot 6: 62–73.

Gordois A, Shearer A, Scuffham P, Oglesby A, Tobian JA. 2003. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26: 1790–1795.

Shearer A, Scuffham P, Gordois A, Oglesby A. 2003. Predicted costs and outcomes of reduced vibration detection in the UK. The Diabetic Foot 6: 30–37.

Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, de Pouvourville G. 2003. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. Journal of Thrombosis and Haemostasis 1: 2167–2174.

Colagiuri S, Colagiuri R, Conway B, Grainger D, Davey P. 2003. DiabCo$t Australia: assessing the burden of type 2 diabetes in Australia. Canberra: Diabetes Australia.

Australia Consortium. National Breast Cancer Centre. 2003. Multidisciplinary Care in Australia: a National Demonstration Project in Breast Cancer.

Le Chevalier T, Brown A, Natale R, Scagliotti G, Vansteenkiste J, Van Meerbeeck J, Rosell R, Rudd R, Danson S, Thatcher N, Schiller J. 2003. Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data. Lung Cancer 41(Suppl 2):70 (abstract 0-239).

Bischoff HG, Tilden D, Kielhorn A, Heuser C. 2003. Gesamttherapiekosten—Analyse fur platin-haltige neue chemotherapien. Krankenhauspharmazie 24:439–445.

Lees M, Aldridge GJR, Davey PJ, Gorgievski M. 2003. Economic evaluation of photodynamic therapy with verteporfin (letter). Ophthalmology 110: 1263–1264.
Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N. 2003. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. European Journal of Health Economics 4: 216–221.

Medical Services Advisory Committee (MSAC). 2003. M-Vax—a treatment for patients with advanced stage III melanoma. August 2002. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee (MSAC). 2003. Intradiscal electrothermal anuloplasty—a treatment for patients with chronic lower back pain due to anular disruption of contained herniated discs. November 2002. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee (MSAC). 2003. LeukoScan—For use in diagnostic imaging of the long bones and feet in patients with suspected osteomyelitis, including those with diabetic foot ulcers. May 2003. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee (MSAC). 2003. M2A Capsule Endoscopy. August 2003. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Luxford K, Evans A, Zorbas H, Ewan C, Redman S, Rainbird K, Price N. 2003. Changing service delivery: outcomes of the National Multidisciplinary Care Demonstration Project. Clinical Oncological Society of Australia (COSA), 30th Annual Scientific Meeting, 25–28 November 2003, Perth, Australia. Podium presentation.

Luxford K, Evans A, Rainbird K, Zorbas H, Redman S, Price N, Ewan C. 2003. Systems change to support multidisciplinary care (MDC) for women with breast cancer—evaluation of a national program. Health Services Research Association of Australia and New Zealand, 3rd Health Services and Policy Research Conference, 16–19 November 2003, Melbourne, Australia. Poster presentation.

Lees M, Graham-Clarke P, Davey P, Thiebaud D, Grainger D. 2003. Cost-effectiveness of teriparatide in the prevention of osteoporotic fractures in Australian men and women. 4th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, 14–17 November 2003, Nice, France. Podium presentation.

Lees M, Graham-Clarke P, Davey P, Thiebaud D, Grainger D. 2003. Cost-effectiveness of raloxifene to prevent osteoporotic fractures among postmenopausal women in Australia. 4th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, 14–17 November 2003, Nice, France. Poster presentation.

Jackson D, Cockle SM, Aristides M, Sykes DP. 2003. The cost of osteoporotic fractures in females in the UK: an epidemiological model. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Aristides M, Jackson D, Liepa AM, Leighl N, Shepherd FA. 2003. Costs of managing toxicities in non-small cell lung cancer with pernetrexed compared to docetaxel as second-line chemotherapy: application to the UK setting. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Tilden D, Aristides M, Stynes G, Lis J, Orlewska E, Krzakowski M, Jassem J, Wlodarczyk H, Zaluski J. 2003. The cost of gemcitabine/cisplatin compared with four other novel chemotherapeutic agents in Poland. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Adams J, Tilden D, Mernagh P. 2003. Utility valuation from the patient perspective of treatment outcomes in osteoarthritis. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Cockle SM, Jackson D, Aristides M, Sykes DP. 2003. The burden of osteoporosis in Europe: an epidemiological model. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Gillberg C, Lothgren M, Fitzgerald P, Cottrell S, Burridge J, Aristides M. 2003. Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: A meta-analysis of safety data incorporating active comparator and placebo controlled trials. European Society for Child and Adolescent Psychiatry (ESCAP) 12th International Congress, 28 September–1 October 2003, Paris, France. Poster presentation.

Davey P, Colagiuri S, Conway B, Grainger D, Colagiuri R, Graham-Clarke P, Fitzgerald P, Le Reun C, Price N. 2003. Cost of type 2 diabetes care in Australia—the DiabCost study. ISPOR 1st Asia Pacific Conference, 1–3 September 2003, Kobe, Japan. Poster presentation.

Davey P, Lees M, Makino K. 2003. Mandatory inclusion of pharmacoeconomics in drug funding: Lessons from the Australian approach 1993–2003. ISPOR 1st Asia Pacific Conference, 1–3 September 2003, Kobe, Japan. Poster presentation.

Davey P, Fitzgerald P, Birinyi-Strachan L. 2003. Evidence on the relative effectiveness and safety of olanzapine and risperidone over time. ISPOR 1st Asia Pacific Conference, 1–3 September 2003, Kobe, Japan. Poster presentation.

Montgomery W, Christova L, deCastella A, Fitzgerald P, Filia K, Collins J, Davey P, Kulkarni J. 2003. Changes over time in self reported outcomes and social functioning in a cohort of people with schizophrenia: Is treatment moving forward? Society of Biological Psychiatry Meeting, 15–17 May, 2003, San Francisco, California. Poster presentation.

Tilden D, Schulz M, Davey P, Noble I. 2003. A utility valuation study assessing treatment outcomes in osteoarthritis. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.

Christova L, Davey P, Jackson D, Montgomery W, de Castella A, Fitzgerald P, Brewer K, Filia K, Collins J, Kulkarni J. The health care costs of schizophrenia in Australia: 18-month follow-up results. ISPOR 8th Annual International Meeting, 18–21 May, 2003, Arlington, VA, USA.

Davey P, Lees M, Graham-Clarke P. 2003. Cost-effectiveness of raloxifene for the prevention of osteoporotic fractures in Australia. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.

Davey P, Lees M. 2003. Public subsidy of pharmaceuticals: the economic case for and against government intervention. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.

Davey P, Mudge M, Croker V, Aldridge G, Fitzgerald P. 2003. A meta-analysis and common comparator analysis of olanzapine versus ziprasidone and aripiprazole. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.

Lees M, Davey P, Price N, Aldridge G, Mudge M, Stokes J. 2003. Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case for Australia. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.
Colagiuri S, Conway B, Grainger D, Davey P, Colagiuri R, Graham-Clarke P, Fitzgerald P, Le Reun C, Price N. 2003. Cost of type 2 diabetes care in Australia—the DiabCost study. ISPOR 8th Annual International Meeting, 18–21 May 2003, Arlington, VA. Poster presentation.

Croker V, Coleman K, Mudge M, Aldridge G, Davey P, Castle D. 2003. A meta-analysis of randomised clinical trials comparing olanzapine with other antipsychotic agents used in the treatment of schizophrenia. International Congress on Schizophrenia Research, 29 March–2 April 2003, Colorado Springs, Colorado, USA.

Montomery W, Croker V, Coleman K, Davey P, Jackson D, Mullen K. 2003. Valuing the safety and efficacy of treatments for schizophrenia by means of a quadrant approach and time trade off survey. International Congress on Schizophrenia Research, 29 March–2 April 2003, Colorado Springs, Colorado, USA.

2002

Gordois AL, Scuffham PA, Gibbons D. 2002. The cost-effectiveness of outreach respiratory care for COPD patients. Professional Nurse 17: 504–507.

Tilden D, Aristides M, Meddis D, Burns T. 2002. An economic evaluation of quetiapine and haloperidol in the treatment of schizophrenic patients partially responsive to previous antipsychotics. Clinical Therapeutics 24:1648–1667.

Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D. 2002. Economic evaluation of gemcitabine in the treatment of non-small cell lung cancer. Pharmacoeconomics 20:325–337.

Schulz MW, Chen J, Woo HH, Keech M, Watson ME, Davey PJ. 2002. A comparison of techniques for eliciting patient preferences in patients with benign prostatic hyperplasia. Journal of Urology 168:155–159.

Aristides M, Chen J, Schulz M, Williamson E, Clarke S, Grant K. 2002. Conjoint analysis of a new chemotherapy: willingness-to-pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. Pharmacoeconomics 20:775–784.

Fitzgerald PB, Rolfe T, Brewer K, Filia K, Collins J, Filia S, Adams A, de Castella ARA, Davey P, Kulkarni J. 2002. Depressive, positive, negative and parkinsonian symptoms in schizophrenia. Australian and New Zealand Journal of Psychiatry 36:340–346.

Fitzgerald PEB. 2002. Extended generalized estimating equations for binary familial data from incomplete families. Biometrics 58:718–726.

Medical Services Advisory Committee (MSAC). 2002. Evaluation of near patient cholesterol testing using the Cholestech LDX. August 2001. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee (MSAC). 2002. Low intensity ultrasound treatment for acceleration of bone fracture healing—Exogen™ bone growth stimulator. November 2001. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee (MSAC). 2002. Recombinant human thyroid-stimulating hormone (rhTSH)—diagnostic agent for use in well-differentiated thyroid cancer. August 2002. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Aristides M, Weston AR, Fitzgerald P, Le Reun C, Schulz M, Maniadakis N, Kielhorn A. 2002. Patient preference and willingness-to-pay in five European countries for Humalog Mix25 compared to Humulin 30/70 for the treatment of type 2 diabetes. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Podium presentation. (Value in Health 5:448 [abstract]).

Davey P, Lees M, Graham-Clarke P. 2002. The cost-effectiveness of raloxifene compared with no drug therapy for the prevention of osteoporotic fractures when HRT is inappropriate: the case of Australia. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Podium presentation. Podium presentation. (Value in Health 5:455 [abstract]).

Christova L, Davey P, Jackson D, Montgomery W, deCastella A, Fitzgerald P, Brewer K, Filia K, Collins J, Kulkarni J. 2002. The health care costs of schizophrenia in Australia: 18-month follow-up results. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam. The Netherlands. Poster presentation. (Value in Health 5:514 [abstract]).

Tilden D, Aristides M, Kielhorn A, Bhalla S. 2002. Major determinants of cost in advanced non-small-cell lung cancer chemotherapy regimens in France. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:538 [abstract]).

Kielhorn A, Aristides M, Tilden DP, Bhalla S. 2002. Average total cost of treating advanced non-small-cell lung cancer patients in Spain using various chemotherapy doublets. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:539 [abstract]).

Aristides M, Lees M, Tilden DP, Kielhorn A, Stynes G. 2002. Gemzar retrospective economic analysis ofclinical trials (GREAT) in the treatment of non-small-cell lung cancer: a multi-country cost-minimisation analysis. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:541 [abstract]).

Aristides M, Tilden D, Lees M, Kielhorn A, Bhalla S. 2002. In the UK Gemzar doublet has lowest total treatment costs for NSCLC compared to four other chemotherapy doublets. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:541 [abstract]).

Tilden DP, Aristides M, Stynes G, Kielhorn A, Bhalla S. 2002. A comparison of the costs of gemcitabine/cisplatin and gemcitabine/carboplatin combination regimens in the treatment of advanced NSCLC in the UK and France. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:542 [abstract]).

Brown A, Aristides M, Fitzgerald P, Davey P, Bhalla S, Kielhorn A. 2002. Examining preferences and time trade-off utility for gemcitabine plus cisplatin in the treatment of bladder cancer: a survey using discrete choice conjoint analysis in the UK. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation. (Value in Health 5:543 [abstract]).

Coleman K, Mudge M, Aldridge G, Davey P, Croker V, Castle D. 2002. A meta-analysis of randomised clinical trials comparing olanzapine with other antipsychotic agents used in the treatment of schizophrenia. 7th Biennial Australasian Schizophrenia Conference, 24–26 October 2002, Sydney, Australia.

Weston AR, Norris SK, Aristides M, Christova L, Lees L. Conducting a large post-marketing surveillance study in Australian general practice: a challenging methodology leads to methodological challenges. 2nd International Clinical Trials Symposium, 21–23 October 2002, Sydney, Australia. Poster presentation.

West R, Powell SR, Marsh HS, Browning DC, Aristides M, Brown A. 2002. Effectiveness of bupropion SR (ZybanTM) treatment for 7–9 weeks in aiding smoking cessation. 4th European Conference of the SRNT, 3–5 October 2002, Santander, Spain. Poster presentation.

Gonzales D, Powell SR, Marsh HS, Brown A, Fitzgerald P. 2002. A pooled analysis confirms smoking abstinence rates with bupropion SR (ZybanTM) are similar in men and women. 4th European Conference of the SRNT, 3–5 October 2002, Santander, Spain. Poster presentation.

Gonzales D, Powell SR, Bohm B, Brown A, Fitzgerald P. 2002. Abstinence rates with bupropion SR (ZybanTM) are similar in men and women. 4th European Conference of the SRNT, 3–5 October 2002, Santander, Spain. Poster presentation.

Jarvis MJ, Powell SR, Marsh HS, Browning D, Aristides M, Brown A. 2002. A meta-analysis of clinical studies confirms the effectiveness of bupropion SR (ZybanTM) in smoking cessation. 4th European Conference of the SRNT, 3–5 October 2002, Santander, Spain. Poster presentation.

Gorgievski M, Davey P. 2002. Development of a forecasting model to predict sales of a range of drugs in Australia: objectives and methods. Presentation at 24th Australian Conference of Health Economists, 17–18 July 2002, Sydney, Australia.

Croker V, Montgomery W, Mullen K, Coleman K, Davey P. How to compare the safety and efficacy of antipsychotic therapies, with a lack of head to head trial evidence, the example of olanzapine versus quetiapine. 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, (CINP), 23–27 June 2002, Montreal, Canada.

Davey P, Rajan N. 2002. Exploring the derivation of utility values using a discrete-choice conjoint analysis method—a cost-utility analysis of gemcitabine plus cisplatin for the treatment of bladder cancer. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Podium presentation. (Value in Health 5:131 [abstract]).

Lees M, Davey P, Aldridge G, Schulz M, Aristides M. 2002. Economic evaluation of photodynamic therapy with verteporfin for predominantly classic, subfoveal CNV secondary to age-related macular degeneration. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation. (Value in Health 5:248 [abstract]).

Schulz M, Noble I, Tilden D, Davey P, Crowley S. 2002. Modelled cost-utility analysis of rofecoxib and traditional non-steroidal therapies for treatment of chronic osteoarthritis. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation. (Value in Health 5:178 [abstract]).

Kielhorn A, Maniadakis N, Aristides M, Lees M, Tilden D. 2002. Retrospective cost analysis of Gemzar™ in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Germany. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation. (Value in Health 5:195 [abstract]).

Adams J, Davey P, Jackson D, Croker V, Aristides M, Mullen K, Montgomery W. 2002. Using a community sample to derive utility values of schizophrenia treatment outcomes from a time trade-off methodology. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation. (Value in Health 5:233 [abstract]).

Aristides M, Tilden D, Robinson P, Weston A, Davey P, Aldridge G. 2002. A decision-analytic model to compare the cost of methyl aminolevulinate photodynamic therapy with standard treatments in the UK for difficult-to-treat basal cell carcinoma and actinic keratosis. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation. (Value in Health 5:245 [abstract]).